×

Compositions for allogeneic cell therapy

  • US 7,435,592 B2
  • Filed: 05/04/2004
  • Issued: 10/14/2008
  • Est. Priority Date: 05/13/2003
  • Status: Active Grant
First Claim
Patent Images

1. A composition of T-cells coated with anti-CD3 and anti-CD28 mAbs wherein the anti-CD3 and anti-CD28 are cross-linked by biodegradable particles coated with an agent reactive against said mAbs, and wherein said activated T-cells are suspended in an infusion media suitable for intravenous infusion at a concentration of at least 107 cells per ml of the infusion media.

View all claims
  • 5 Assignments
Timeline View
Assignment View
    ×
    ×